Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The eosinophil-to-monocyte ratio (EMR) has emerged as a promising biomarker for assessing inflammation in various diseases, and this study aims to investigate its potential in predicting asthma exacerbations.
Methods: This cross-sectional study used data from the National Health and Nutrition Examination Survey (NHANES) 1999-2020. A total of 4,738 adults were included in the analysis, and weighted analyses were performed to ensure a representative sample of the general population. The relationship between EMR and asthma exacerbation risk was assessed using multivariable logistic regression with progressively adjusted covariates across multiple models. Subgroup analyses were performed by stratifying key covariates to explore interactions. Restricted cubic spline (RCS) analysis was applied to evaluate non-linear relationships. Sensitivity analyses confirmed the robustness and reliability of the results.
Results: Elevated EMR levels were significantly associated with an increased risk of asthma exacerbations (p < 0.001 in all models). In the highest EMR quartile (Q4), the odds ratio for exacerbation compared to the lowest quartile (Q1) was 1.54 (95% CI: 1.23, 1.93) in Model 1, increasing to 1.56 (95% CI: 1.24, 1.97) in Model 2 and 1.58 (95% CI: 1.24, 2.02) in Model 3, after further adjustments. Subgroup analyses showed consistent associations across various characteristics (all p for interaction > 0.05), while RCS analysis revealed a linear relationship without threshold effects (p for nonlinear > 0.05).
Conclusion: EMR demonstrates strong potential as a biomarker for predicting asthma exacerbations, with implications for personalized asthma management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11992703 | PMC |
| http://dx.doi.org/10.1186/s12890-025-03617-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sex differences in childhood atopic disease and the role of sex-steroid metabolites.
J Allergy Clin Immunol Pract
September 2025
COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Background: Studies have described sex differences in childhood asthma, allergy, and atopic dermatitis, but the development and clinical phenotype of these differences remain poorly understood.
Objective: To characterize sex differences in atopic disease throughout childhood and study the potential role of sex-steroid metabolites.
Methods: We examined sex differences in asthma, allergy, and atopic dermatitis using longitudinal generalized estimating equation models in the COPSAC (n=411) and COPSAC (n=700) birth cohorts.
Bronchiectasis in France: data on disease characteristics in 630 patients from the European Bronchiectasis registry (EMBARC).
Respir Med Res
August 2025
Cystic Fibrosis Center Service de Pneumologie Pôle des Voies Respiratoires, Hôpital Larrey CHU de Toulouse, Toulouse, France.
Background: Little is known about the characteristics of adults with bronchiectasis in France.
Methods: A descriptive cross-sectional study was conducted to describe the characteristics of adults (≥18 years) with clinically-significant bronchiectasis, diagnosed on a combination of respiratory symptoms and CT scan findings, and followed in 18 participating centers. Data on, etiology, lung function, symptoms, microbiology, treatments and quality of life were collected.
Baseline characteristics of patients from the Brazilian Severe Asthma Registry: the REBRAG study.
J Bras Pneumol
September 2025
. Programa de Pós-Graduação em Ciências Médicas, Universidade Federal de Santa Catarina, Florianópolis (SC) Brasil.
Objective: To describe the impact of severe asthma in a real-life cohort in Brazil, reporting on baseline clinical characteristics, access to treatment, and clinical remission under treatment with biologics.
Methods: Severe asthma patients > 6 years of age were recruited from 23 centers in Brazil. Data on clinical characteristics, lung function, biomarkers, prescribed therapies, and clinical remission under treatment were collected at the baseline visit.
Sputum Eosinophil and Macrophage Changes After Aspirin Challenge in Patients With Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease.
Clin Transl Allergy
September 2025
Second Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.
Background: Induced sputum cell count is crucial for assessing airway inflammatory phenotypes. This study investigated how aspirin-induced bronchospasm affects sputum cell counts in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD), comparing systemic versus local aspirin administration.
Methods: Seventy-eight patients with N-ERD and 39 with aspirin-tolerant asthma (ATA) participated.
Predictors of mortality and hospitalised exacerbations in obstructive airway diseases.
ERJ Open Res
September 2025
Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Background: In Belgium, age-standardised hospital admission and mortality rates for asthma and COPD are higher than the European average. Understanding the factors that lead to a hospitalised exacerbation and/or mortality is needed to optimise patient management.
Methods: Patients ≥18 years old obtaining two claims for drugs for obstructive airway diseases (ATC code R03) in 1 year between 2017 and 2022 were identified in Belgian nationwide claims-based data.